Related Experiment Video

Updated: Jun 24, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3

Jiahao Jiang1,2,3, Jinming Xu3, Longhua Ou3

  • 1Department of Urology, Shenzhen Second People's Hospital, Clinical College of Anhui Medical University Shenzhen, Guangdong, P. R. China.

American Journal of Cancer Research
|June 11, 2024
PubMed

Insights

Low expression of Integral membrane protein 2A (ITM2A) correlates with advanced bladder cancer. Restoring ITM2A inhibits tumor growth and metastasis, suggesting ITM2A as a potential prognostic marker and therapeutic target for bladder cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urological Cancer Research

Background:

  • Bladder cancer is a common malignancy requiring novel prognostic and therapeutic strategies.
  • Integral membrane protein 2A (ITM2A) has emerged as a potential tumor suppressor.
  • Understanding ITM2A's role in bladder cancer is crucial for developing new treatments.

Purpose of the Study:

  • To investigate the correlation between ITM2A expression and bladder cancer progression.
  • To elucidate the functional role of ITM2A in bladder cancer cell behavior.
  • To explore the underlying molecular mechanisms of ITM2A's tumor-suppressive activity.

Main Methods:

  • Analysis of ITM2A expression in bladder cancer tissues.
  • Correlation of ITM2A levels with clinical parameters (tumor grade, AJCC stage, survival).
  • In vitro experiments assessing the effects of ITM2A modulation on cell proliferation, migration, and invasion.
  • Investigation of ITM2A's impact on the IL-6/STAT3 signaling pathway.

Main Results:

  • Low ITM2A expression is significantly associated with higher tumor grade, advanced AJCC stage, and poorer overall survival in bladder cancer patients.
  • Re-expression of ITM2A suppressed bladder cancer cell proliferation, migration, and invasion.
  • Suppression of ITM2A enhanced these malignant phenotypes.
  • ITM2A inhibits bladder cancer progression by suppressing IL-6-induced STAT3 activation.

Conclusions:

  • ITM2A functions as a tumor suppressor in bladder cancer.
  • ITM2A expression levels can serve as a prognostic predictor for bladder cancer.
  • Targeting ITM2A may offer a promising therapeutic strategy for bladder cancer management.
Keywords:
ITM2Abladder cancercell progressionphosphorylation of STAT3tumor suppressor

More Related Videos

Mouse Bladder Wall Injection03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.0K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K